granulomatosis with polyangiitis
Information
- Disease name
- granulomatosis with polyangiitis
- Disease ID
- DOID:12132
- Description
- "An autoimmune disease that is characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tract, glomerulonephritis, vasculitis, and the presence of antineutrophil cytoplasmatic autoantibodies (ANCAs) in patient sera, and is located_in lung, located_in kidney, located_in skin resulting from an autoimmune attack by antineutrophil cytoplasmic antibodies against small and medium-size blood vessels." [url:https\://en.wikipedia.org/wiki/Granulomatosis_with_polyangiitis]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03919435 | Active, not recruiting | Phase 1/Phase 2 | TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis | March 27, 2019 | September 30, 2025 |
| NCT02108860 | Active, not recruiting | Phase 3 | Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) | April 25, 2015 | September 2023 |
| NCT05716334 | Active, not recruiting | Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator | June 15, 2021 | September 15, 2025 | |
| NCT01933724 | Active, not recruiting | Phase 3 | The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach | February 17, 2014 | December 31, 2023 |
| NCT01940094 | Active, not recruiting | Phase 3 | The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach | February 2014 | December 2024 |
| NCT00315393 | Completed | Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis | April 2006 | December 2019 | |
| NCT01613599 | Completed | An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | June 20, 2012 | April 28, 2017 | |
| NCT01731561 | Completed | Phase 3 | Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis | November 16, 2012 | April 5, 2016 |
| NCT01750697 | Completed | Phase 2 | A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis | May 23, 2013 | May 10, 2018 |
| NCT01862068 | Completed | Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) | May 25, 2012 | May 18, 2018 | |
| NCT02169219 | Completed | Phase 4 | Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis | June 2014 | November 1, 2017 |
| NCT03410290 | Completed | Journey of Patients With Vasculitis From First Symptom to Diagnosis | January 11, 2018 | May 21, 2018 | |
| NCT03430388 | Completed | N/A | Yellow Fever Vaccine in Patients With Rheumatic Diseases | January 31, 2018 | February 24, 2019 |
| NCT04280601 | Completed | N/A | PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis | August 1, 2020 | March 1, 2023 |
| NCT05703802 | Completed | Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. | February 1, 2022 | November 1, 2022 | |
| NCT04871191 | Not yet recruiting | Phase 2 | Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis | March 2023 | January 2027 |
| NCT03482479 | Recruiting | Phase 2 | Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis | February 4, 2019 | December 31, 2024 |
| NCT04944524 | Recruiting | Phase 4 | Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA | July 1, 2021 | July 1, 2024 |
| NCT05376319 | Terminated | Phase 2 | PR3-AAV Resilient Remission or PRRR | June 30, 2023 | May 7, 2024 |
| NCT01586858 | Terminated | Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study | May 2012 | May 15, 2014 | |
| NCT02126098 | Unknown status | Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis | May 2014 | December 2017 | |
| NCT03967925 | Unknown status | Phase 2 | Rituximab and Belimumab Combination Therapy in PR3 Vasculitis | February 1, 2019 | November 2023 |
| NCT03782870 | Unknown status | Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis | February 1, 2010 | December 30, 2019 | |
| NCT05353179 | Unknown status | Early Phase 1 | Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers | June 2022 | October 2022 |
| NCT01405807 | Unknown status | Phase 4 | Alemtuzumab for ANCA Associated Refractory Vasculitis | February 2011 | March 2014 |
| NCT01598857 | Withdrawn | Phase 2 | BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis | December 2014 | |
| NCT03182049 | Withdrawn | Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study | December 2020 | May 2023 |
- Disase is a (Disease Ontology)
- DOID:417
- Cross Reference ID (Disease Ontology)
- GARD:7880
- Cross Reference ID (Disease Ontology)
- ICD10CM:M31.3
- Cross Reference ID (Disease Ontology)
- ICD9CM:446.4
- Cross Reference ID (Disease Ontology)
- MESH:D014890
- Cross Reference ID (Disease Ontology)
- MIM:608710
- Cross Reference ID (Disease Ontology)
- NCI:C3444
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:195353004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C3495801
- Exact Synonym (Disease Ontology)
- Necrotizing respiratory granulomatosis
- Exact Synonym (Disease Ontology)
- Wegener granulomatosis, formerly
- OrphaNumber from OrphaNet (Orphanet)
- 900
- MeSH unique ID (MeSH (Medical Subject Headings))
- D014890